Pfizer Inc (PFE)
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
📉 **NEGATIVE** • Medium confidence analysis (61%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (24%) **Content type:** Clinical